SEARCH · Search PubMed

Results for “hypoglycemic”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

SourceResearch connectionFrom yearThrough year

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 289 records · Page 16Linked to original sources

PubMed1990

The oral hypoglycemic agent, U-56324, inhibits the activity of ATP-sensitive potassium channels in cell-free membrane patches from cultured mouse pancreatic B-cells.

U-56324, a hypoglycemic agent derived from nicotinic acid, inhibited the activity of ATP-sensitive potassium channels in excised patches from mouse pancreatic B-cells. The effect of U-56324 on channel activity was reversible and concentration-dependent while it had no effect on single channel conductance. The positional isomer, U-59588, which has relatively little hypoglycemic activity, had no effect on channel properties. U-56324, at the same concentrations, had no effect on calcium-activated potassium channels. The basis for the potentially antidiabetic properties of U-56324 may therefore be due to direct and specific inhibition of ATP-sensitive potassium channels.

Adenosine Triphosphate↗

PubMed1990

Hypoglycemic action of Salvia lavandulifolia Vahl. spp. oxyodon:a contribution to studies on the mechanism of action.

Having previously demonstrated the hypoglycemic action of Salvia lavandulifolia Vahl, subspecies oxyodon, the mechanism of action was further investigated. The hypoglycemic action may be the result of several synchronous mechanisms: a) potentiation of insulin release induced by glucose, b) increased peripheral uptake of glucose, c) decreased intestinal absorption of glucose and d) hyperplasia of the pancreatic islet beta cells (seen after chronic treatment).

Animals↗

PubMed1990

Solid and solution behavior of sulphonylurea complexes with ions of IIA group metals. Molecular modeling of K[Zn(ClCH4SO2NCONHC3H7)3] and action of zinc-sulphonylurea complexes as hypoglycemic agents.

Complexes of Zn2+ with deprotonated suphonylurea as ligands have been synthesized and characterized. Deprotonated sulphonylurea act as bidentate ligands using one nitrogen and one oxygen atom (the ureido oxygen) to bind Zn2+ forming K[Zn(suphonylurea)3]. Using the MMX89 program, a model for K[Zn(ClC6H4SO2NCONHC3H7)3] compound is proposed. Conductometric and potentiometric studies in methanol, for d10 metal-sulphonylurea complexes, demonstrated that zinc, cadmium and silver complexes are 1:1 electrolytes and are protonated in the range 4.2-5.6 pH. UV-Vis study shows no interaction between metal and protonated sulphonylureas in methanol solutions. At 7.34 pH the form of Zn complexes which act as a hypoglycemic agent is [ZnL3]-. Test for hypoglycemic activity reduced glycemia to a statistically significant degree compared to the corresponding free ligands.

Animals↗

PubMed1989

Prescription drug advertising trends: a study of oral hypoglycemics.

A content analysis of oral hypoglycemic drug advertisements was performed in selected medical journals published in the United States from 1963 to 1986. The 665 advertisements subsequently examined were studied for certain predetermined parameters in order to indicate trends. The trend results may be summarized as follows. As an extension of prescription drug advertising trends in general, oral hypoglycemic drug advertising showed an increasing length along with a subsequent decrease in the amount of space devoted to the copy portion of the advertisement. They also showed a decrease in the use of statistical information and rarely made references to competitors. Nongender specific, colored advertisements with product and use related appeals have become more common with the passage of time. Although the rationale and purpose behind advertising is unchanged, the format has changed considerably. These changes are primarily due to the enhancement of print technology and to some extent, the changing social environment.

Administration, Oral↗

PubMed1981

Comparative study on the effects of a hypoglycemic 2-substituted-2-imidazoline derivative (DG-5128) and tolbutamide on insulin secretion from and insulin synthesis in the isolated rat pancreatic islets.

2[2-(4,5-Dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine dihydrochloride sesquihydrate (DG-5128) was found to stimulate the glucose-primed insulin secretion from the isolated rat pancreatic islets throughout the incubation period, unlike tolbutamide which stimulated it only in the initial phase of incubation. The effect of DG-5128 was more pronounced at a higher glucose concentration (5 mg/ml). In the islet perifusion study, DG-5128 was also found to stimulate the glucose-induced insulin secretion in both the first and the second phases of the reaction, in contrast to tolbutamide which stimulated only the first phase of insulin secretion from the perifused islets. DG-5128 gave no significant effect on the glucose-stimulated increase in incorporation of [3H]leucine into the proinsulin and insulin fractions, while tolbutamide significantly inhibited the incorporation especially at a low glucose concentration (1 mg/ml). These and the previous findings indicate that DG-5128 is a new class of hypoglycemic agent with a unique mode of action different from the known hypoglycemics ever reported.

Animals↗

PubMed1985

Hypoglycemic constituents of Panax ginseng.

This article reviews the recent progress in the identification of hypoglycemic and insulino-mimetic principles in ginseng. Hitherto five types of substances have been discovered. They include five glycans designated panaxans A to E, adenosine, a carboxylic acid, a peptide with a molecular weight of 1400 and lacking in basic amino acid residues, and a fraction designated DPG-3-2 prepared from the water extract of ginseng. The structure of panaxan A has been partially elucidated and the glycans have been demonstrated to elicit hypoglycemia in both normal and diabetic mice. DPG-3-2 exerted its hypoglycemic action or provoked insulin secretion in diabetic and glucose-loaded normal mice while having no effect on normal mice. Adenosine, the carboxylic acid and the mol. wt 1400 peptide inhibited catecholamine-induced lipolysis in rat epididymal fat pads. EPG-3-2, a fraction related to DPG-3-2, also exhibited antilipolytic activity.

Adenosine↗

PubMed1984

A study of the hypoglycemic effect of some Mexican plants.

Diabetes mellitus is a disease that annually causes many deaths, and to date no really efficient remedy has been found. We studied a number of plants traditionally used in Mexico against diabetes, some of them since prehispanic times. Specimens of each species were collected and extracts from them were tested on CD1 strain mice with alloxan-induced diabetes. Hypoglycemic activity was determined by the O-toluidine and the Dextrostix tape methods. Several of the plants showed a marked hypoglycemic effect.

Administration, Oral↗

PubMed1988

Hypoglycemic effects of Teucrium polium.

Teucrium polium has a folk reputation as a hypoglycemic agent. The hypoglycemic activity of an aqueous decoction of plant aerial parts was tested in normoglycemic and streptozotocin-hyperglycemic rats. Results indicate that this extract caused significant reductions in blood glucose concentration 4 h after intravenous administration and 24 h after intraperitoneal administration. This effect could be due to enhancement of peripheral metabolism of glucose rather than an increase in insulin release.

Animals↗

PubMed1995

Biotransformation of linogliride, a hypoglycemic agent in laboratory animals and humans.

Following oral administration of linogliride, a hypoglycemic agent, to rat (50 mg kg-1), dog (30 mg kg-1), and man (100 mg per subject), plasma, urine, and fecal extract sample pools were obtained. Nine metabolites plus unchanged linogliride were isolated and identified. The number of metabolites identified were: rat (5), dog (9), and man (1). In each species, more than 78% of the administered dose was recovered in the urine pools. Identified metabolites were estimated to account for > 82% of the total amounts of drug-related sample in urine pools and > 50% in plasma and fecal extract pools. Formation of linogliride metabolites in the three species can be described by four proposed pathways: pyrrolidine hydroxylation, aromatic hydroxylation, morpholine hydroxylation, and imino-bond cleavage. Comparison of the proposed metabolic pathways among species reveals a similarity between rat and dog. In these two species, pyrrolidine hydroxylation was quantitatively the most important pathway, with 5-hydroxylinogliride and dominant hypoglycemic active metabolite in all sample pools. Further oxidation of 5-hydroxylinogliride resulted in the formation of five minor metabolites. The other three pathways appeared to be quantitatively unimportant. Metabolism of linogliride in man occurred to a very limited extent. More than 90% of the total linogliride-related material in plasma was the unchanged drug. Greater than 76% of the administered dose was excreted unchanged in the urine. Only 5-hydroxylinogliride was identified in minor amounts in human samples.

Animals↗

PubMed2004

Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.

OBJECTIVE: To see if insulin glargine improves glycemic control in a clinical setting. RESEARCH DESIGN AND METHODS: A questionnaire and electronic database were used to assess glycemic parameters for 292 type 1 diabetic subjects taking > or =4 injections per day and receiving glargine as their only long-acting basal insulin for at least 6 months. Sixty-three subjects were taking glargine in the morning, 125 were taking glargine in the evening, and 104 were splitting the glargine dose between the morning and evening. RESULTS: The mean (+/-S.D.) age and duration of diabetes were 32 +/- 10 years and 15.9 +/- 10.3 years, respectively. The mean (+/-S.E.M.) durations of treatment with glargine were 13.1 +/- 0.6 months, 12.2 +.- 0.4 months, and 14.3 +/- 0.5 months for the morning, evening, and split treatment groups, respectively (P < 0.01). The A1C values improved significantly from baseline for the evening and the split dosage groups or when all groups were combined. The mean basal insulin dose was significantly reduced at the end of the study in all the three groups from baseline with no change in the short-acting insulin dose. The number of severe hypoglycemic episodes decreased from 379 in the year prior to glargine treatment to 167 in the post-glargine year. The weight gain was significantly higher in the group that took the split glargine dose (P < 0.01). CONCLUSIONS: Similar or improved glycemic control was achieved by administering glargine in the morning, evening, or using a split dose without any further increase in severe hypoglycemic episodes. Splitting the glargine dose did not offer any advantages in glycemic control parameters.

Adult↗

PubMed2004

Hypoglycemic effect of Acosmium panamense bark on streptozotocin diabetic rats.

The hypoglycemic effects of water and butanolic extracts prepared from the bark of Acosmium panamense (Fabaceae) were studied in diabetic rats (streptozotocin (STZ)-induced). Oral application of water extracts at doses of 20 and 200 mg/kg and of butanol extracts at doses of 20 and 100 mg/kg significantly lowered the plasma glucose levels in diabetic rats within 3 h. Glibenclamide was used as reference and showed similar hypoglycemic effect like the extracts. Three structurally new compounds were isolated from the plant and shown to be the main constituents in both extracts.

Animals↗

PubMed2005

Acute and chronic hypoglycemic effect of Ibervillea sonorae root extracts-II.

Ibervillea sonorae's root, or "wareque" (Cucurbitaceae), is widely used in Mexican traditional medicine for the control of diabetes mellitus. In the present study, the hypoglycemic effects produced by the acute and chronic administration of various extracts of Ibervillea sonorae were investigated. Both the traditional preparation (aqueous decoction) and the raw extract (juice) from the root resulted in significant reductions of glycemia in healthy mice after intraperitoneal administration at a dose of 600 mg/kg. Additionally, ground dried root was used to obtain a dichloromethane (DCM) extract and a methanol (MeOH) extract. The DCM extract induced a clear reduction of glycemia in healthy (P < 0.05) and in alloxan-diabetic mice. The intraperitoneally administered DCM extract caused a severe hypoglycemia that produced lethality in all the treated animals when doses of 300 and 600 mg/kg body weight were used. Since the DCM extract showed a marked hypoglycemic activity, it was administered daily per os to alloxan diabetic rats, employing corn oil and tolbutamide as controls. After 41 days of DCM extract administration at a dose of 300 mg/kg/day, diabetic rats showed improvement in glycemia, body weight, triglycerides, and GPT in comparison with the diabetic control group. Total cholesterol, GOT, and uric acid blood levels were not affected.

Animals↗

PubMed2005

Hypoglycemic effect of Malmea depressa root on streptozotocin diabetic rats.

The hypoglycemic effects of water, ethanolic and butanolic extracts prepared from the root of Malmea depressa (Baill) R.E. Fries. (Annonaceae) were studied in diabetic rats (streptozotocin induced). Oral application of water extracts at doses of 40 and 80 mg/kg, ethanolic (112 mg/kg) and butanolic (80 mg/kg) extracts significantly lowered the plasma glucose levels in diabetic rats within three hours. Glibenclamide and metformin were used as references and showed similar hypoglycemic effects like the extracts. The three extracts have a similar chemical composition (HPLC analysis).

Animals↗

PubMed2006

Hypoglycemic, vasorelaxant and hepatoprotective effects of Cochlospermum vitifolium (Willd.) Sprengel: a potential agent for the treatment of metabolic syndrome.

Cochlospermum vitifolium (Willd.) Sprengel is a Mexican medicinal plant that is used in the folk medicine for the treatment of hypertension, diabetes, hepatitis and related diseases. The purpose of the present study was to assess the pharmacological properties of different extracts from Cochlospermum vitifolium bark as potential agent for the treatment of some factors related with metabolic syndrome (MS), a complex disease produced for several pathophysiological factors such as visceral fat obesity, insulin resistance, hypertension, dyslipidemia and liver steatosis. Hexane (HECv), dichloromethane (DECv) and methanol (MECv) extracts were subjected to some pharmacological assays to determine their vasorelaxant and hypoglycemic activity. On the other hand, MECv was also evaluated to determine its hepatoprotective effect on sub-chronic experimental assay. HECv showed a significant endothelium-independent relaxation on rat aorta rings (intact endothelium: IC(50)=14.42+/-5.90 microg/mL, E(max)=92.71+/-8.9%; denuded endothelium: IC(50)=27.94+/-4.0 microg/mL, E(max)=78.68+/-4.6%) and MECv produced an endothelium-dependent relaxation (IC(50)=21.94+/-6.87 microg/mL, E(max)=79.12+/-7.80%) on this tissue. Furthermore, HECv (at a dose of 120 mg/kg) also showed a significant decrease of blood glucose levels (p<0.05) on normoglycemic rats. Moreover, MECv (at a dose of 100 mg/kg) also was administered to bile duct-obstructed rats to determine its hepatoprotective activity, showing a statistically significant decrease of serum glutamic-pyruvic transaminase (PGT, 45%) and alkaline phosphatase (APh, 15%) (p<0.05). Finally, we obtained a crystalline polyphenolic compound from MECv by spontaneous precipitation. Those crystals were identified as (+/-)-naringenin by X-ray diffraction, NMR, IR and GC-MS techniques. Results suggest that Cochlospermum vitifolium could be used as a potential agent against MS since it shows hypoglycemic, vasorelaxant and hepatoprotective properties.

Alanine Transaminase↗

PubMed2005

Hypoglycemic effect of crude exopolysaccharides produced by a medicinal mushroom Phellinus baumii in streptozotocin-induced diabetic rats.

The antidiabetic effect of the crude exopolysaccharides (EPS) produced from submerged mycelial culture of Phellinus baumii in streptozotocin (STZ)-induced diabetic rats was investigated. The produced EPS consisted of two different heteropolysaccharides and two proteoglycans. The food intake of the diabetic control rats (STZ) was increased by 28.1%, whereas body weight gain was reduced by 44.1% as compared to the nondiabetic animals (NC). The plasma glucose level in the EPS-fed rats (EPS) was substantially reduced by 52.3% as compared to the diabetic rats (STZ), which is the highest hypoglycemic effect among mushroom-derived materials documented in literature. The activities of alanine aminotransferase (ALT) and asparate aminotransferase (AST) were significantly decreased by administration of P. baumii EPS, thereby exhibiting a remedial role in liver function. The significant increase in weights of liver, spleen, and kidney was observed in diabetic groups (both STZ and EPS) compared to NC. The results suggest that orally administrated P. baumii EPS exhibited considerable hypoglycemic effect in STZ-induced diabetic rats and that these EPS may be useful for the management of diabetes mellitus.

Animals↗

PubMed2004

American ginseng leaf: ginsenoside analysis and hypoglycemic activity.

Previous studies showed that both American ginseng root and American ginseng berry extracts possess hypoglycemic properties. In this study, we investigated whether American ginseng leaves also have similar capabilities. We first analyzed the chemical constituents of American ginseng leaf and determined the content of six major ginsenosides, i.e., Rb(1), Rb(2), Rc, Rd, Re, and Rg(1), by high performance liquid chromatography (HPLC). Subsequently, we evaluated the hypoglycemic effect of American ginseng leaf extract (AGLE) in diabetic ob/ob adult mice. Animals received daily intraperitoneal injections of AGLE 50, 150 mg/kg or vehicle for 12 consecutive days. Fasting blood glucose levels, intraperitoneal glucose tolerance test (IPGTT), body weight and temperature were measured. On day 5, the 150 mg/kg AGLE group had significantly lower fasting blood glucose levels compared to vehicle-treated mice (223.0+/-13.9 mg/dl versus 258.0+/-14.0 mg/dl, P<0.05), while the blood glucose levels in 50 mg/kg group did not decrease significantly. On day 12, the glucose levels in both AGLE-treated groups were reduced significantly compared to vehicle group (180.0+/-10.0 mg/dl and 220.2+/-19.3 versus 268.0+/-10.0 mg/dl, P<0.01 and <0.05, respectively). IPGTT data showed that both AGLE 150 and 50 mg/kg groups significantly increased the glucose disposal on day 12 compared to the vehicle group. In addition, body weight decreased in ob/ob mice after AGLE treatment, and these body weight changes were accompanied by significant increases in body temperature (P<0.05). Our results suggest that AGLE possesses a significant anti-hyperglycemic and thermogenic activity and may prove to be beneficial in improving the management of type 2 diabetes.

Animals↗

PubMed2005

Hypoglycemic activity of polysaccharide, with antioxidation, isolated from cultured Cordyceps mycelia.

Cordyceps sinensis, a well-known traditional Chinese medicine, possesses anti-tumor, immunostimulant and antioxidant activities; however, the identities of active components have not been determined. In our previous study using antioxidant activity-guided fractionation [Li et al., 2003. A polysaccharide isolated from Cordyceps sinensis, a traditional Chinese medicine, protects PC12 cells against hydrogen peroxide-induced injury. Life Sci. 73, 2503-2513], a polysaccharide of molecular weight approximately 210kDa was isolated from cultured Cordyceps mycelia by ion-exchange and sizing chromatography. The isolated polysaccharide, named CSP-1, which has strong anti-oxidation activity, contains glucose, mannose and galactose in the ratio of 1:0.6:0.75. In the present study, we demonstrated the hypoglycemic effect of CSP-1 on normal and alloxan-diabetic mice and streptozotocin (STZ)-diabetic rats. The basal glucose level did not differ significantly among the normal mice. CSP-1 (at 200 and 400mg/kg body wt./day for 7 days, p.o.), however, significantly reduced the blood glucose level by 12.0+/-3.2% and 22.5+/-4.7% in normal mice, respectively (p<0.05). When administered at a dose of higher than 200mg/kg body wt. daily for 7 days, CSP-1 produced a significant drop in blood glucose level in both STZ-induced diabetic rats and alloxan-induced diabetic mice. The serum insulin levels in diabetic animals were also increased by administration of CSP-1 (p<0.05). CSP-1 with hypoglycemic properties increased circulating insulin level in diabetic animals, which suggests that CSP-1 may stimulate pancreatic release of insulin and/or reduce insulin metabolism.

Administration, Oral↗

PubMed1997

Potentiation of the insulinotropic and hypoglycemic action of gliquidone by succinic acid esters.

The monoethyl, monopropyl and monoisopropyl esters of succinic acid, administered intravenously at the dose of 2 micromol/g body weight, were found to increase the insulinotropic action of gliquidone (0.2 nmol/g body weight) in anaesthetized rats. The monoisopropyl ester of succinic acid also doubled the hypoglycemic action of gliquidone. These findings indicate that it is possible to design esters of succinic acid that are devoid of the risk of generating methanol by intracellular hydrolysis, and yet susceptible to increase both the insulinotropic and hypoglycemic responses to antidiabetic agents.

Animals↗